分子诊断药相关的联盟和授权合约 (2016～2024年)

本报告提供分子诊断药相关的近来 (2016～2024年) 的联盟授权合约趋势相关分析，彙整整体交易数量的转变，及财务方面 (付款条件) 的倾向，由于主要企业 (全25公司) 的交易形成的动向，契约条件的倾向，各技术详细内容趋势等调查，近几年主要的联盟交易内容等详细资讯，为您概述为以下内容。

目录

摘要整理

第1章 简介

第2章 分子诊断药相关的交易形成的倾向

• 简介
• 分子诊断药相关交易的长期趋势
• 分子诊断药相关的交易:各交易类型
• 分子诊断药相关最活跃的交易业者
• 分子诊断药相关的交易:各治疗领域
• 分子诊断药相关的交易:各业界
• 分子诊断药相关的交易:交易条件
  • 分子诊断药相关的交易:交易总额
  • 分子诊断药相关的交易:预付款金
  • 分子诊断药相关的交易:阶段性付款
  • 分子诊断药相关的交易:使用费率

第3章 分子诊断药相关的主要交易

• 简介
• 分子诊断药相关的主要的交易:以契约金额为准

第4章 用分子诊断药相关最活跃的交易企业

• 简介
• 分子诊断药相关交易上最活跃的企业
• 分子诊断药相关交易上最活跃的企业:简介

第5章 分子诊断药相关的契约缔结一览

• 简介
• 分子诊断药相关的契约缔结一览

第6章 分子诊断药相关的交易:各技术种类

• 交易一览
• 交易一览:分子诊断药相关，各企业 (ABC顺序)
• 交易一览:分子诊断药相关，各交易类型
• 交易一览:分子诊断药相关，各治疗领域
• 交易的种类定义
• 关于Biopharma Research Ltd
• 目前联盟
• 目前契约
• Current Partnering出版的最近报告标题

Molecular Diagnostics Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the molecular diagnostics deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of molecular diagnostics deals from 2016 to 2024.

The report provides a detailed understanding and analysis of how and why companies enter molecular diagnostics deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 740 molecular diagnostics deals announced since 2016 including financial terms where available including links to online deal records of actual molecular diagnostics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of molecular diagnostics dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in molecular diagnostics dealmaking since 2016.

Chapter 3 provides an overview of the leading molecular diagnostics deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in molecular diagnostics dealmaking with a brief summary followed by a comprehensive listing of molecular diagnostics deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of molecular diagnostics deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of molecular diagnostics partnering deals signed and announced since Jan 2016. The chapter is organized by specific molecular diagnostics technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in molecular diagnostics deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Molecular Diagnostics Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse molecular diagnostics collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Molecular Diagnostics Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of molecular diagnostics trends and structure of deals entered into by leading biopharma companies worldwide.

Molecular Diagnostics Collaboration and Licensing Deals includes:

• Trends in molecular diagnostics dealmaking in the biopharma industry
• Directory of molecular diagnostics deal records covering pharmaceutical and biotechnology
• The leading molecular diagnostics deals by value
• Most active molecular diagnostics licensing dealmakers
• Molecular Diagnostics Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in molecular diagnostics dealmaking

• 2.1. Introduction
• 2.2. Molecular diagnostics deals over the years
• 2.3. Most active molecular diagnostics dealmakers
• 2.4. Molecular diagnostics deals by deal type
• 2.5. Molecular diagnostics deals by therapy area
• 2.6. Molecular diagnostics deals by industry sector
• 2.7. Deal terms for molecular diagnostics deals
  • 2.7.1 Molecular diagnostics deals headline values
  • 2.7.2 Molecular diagnostics deal upfront payments
  • 2.7.3 Molecular diagnostics deal milestone payments
  • 2.7.4 Molecular diagnostics royalty rates

Chapter 3 - Leading molecular diagnostics deals

• 3.1. Introduction
• 3.2. Top molecular diagnostics deals by value

Chapter 4 - Most active molecular diagnostics dealmakers

• 4.1. Introduction
• 4.2. Most active molecular diagnostics dealmakers
• 4.3. Most active molecular diagnostics deals company profiles

Chapter 5 - Molecular diagnostics contracts dealmaking directory

• 5.1. Introduction
• 5.2. Molecular diagnostics contracts dealmaking directory

Chapter 6 - Molecular diagnostics dealmaking by technology type

• Deal directory
• Deal directory - Molecular diagnostics deals by company A-Z
• Deal directory - Molecular diagnostics deals by deal type
• Deal directory - Molecular diagnostics deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Molecular diagnostics deals since 2016
• Figure 2: Active molecular diagnostics dealmaking activity - 2016 - 2024
• Figure 3: Molecular diagnostics deals by deal type since 2016
• Figure 4: Molecular diagnostics deals by therapy area since 2016
• Figure 5: Molecular diagnostics deals by industry sector since 2016
• Figure 6: Molecular diagnostics deals with a headline value
• Figure 7: Molecular diagnostics deals with an upfront value
• Figure 8: Molecular diagnostics deals with a milestone value
• Figure 9: Molecular diagnostics deals with a royalty rate value
• Figure 10: Top molecular diagnostics deals by value since 2016
• Figure 11: Most active molecular diagnostics dealmakers 2016 - 2024
• Figure 12: Molecular diagnostics deals by technology type since 2016